Smoking Cessation Medication And Rewards Using a Teamlet to Treat Tobacco Use Disorder (SMARTTT 2.0) Among Persons With HIV: A Multi-site Hybrid Type 2 Effectiveness-implementation Trial

Cigarette smoking is an important cause of illness and death among persons with HIV (PWH). This project will study the impact of adding contingency management (use of financial rewards) to receiving medications and counseling on promoting smoking abstinence and other health outcomes among PWH. As treatments will be provided by clinical pharmacists and other team members in HIV clinics, factors relevant for implementing this model to inform real-world practice will also be evaluated.

Start Date30 Sep 2027

Sponsor / Collaborator

Yale University

[+1]

NCT07809854

/ Not yet recruitingPhase 4IIT

Evaluating an Innovative Tobacco Treatment Approach for Veterans in Substance Use Disorder Treatment

Veterans with substance use disorders smoke at extraordinarily high rates and have high rates of smoking-related death and disease. It is essential to provide tobacco treatment for Veterans with substance use disorders, but there are unfortunately low rates of smoking treatment engagement within the VA for those with substance use disorders. The goal of this project is to generate preliminary evidence for a smoking intervention program called "Concurrent Substance and Tobacco Outpatient Program" or Co-STOP. Co-STOP aims to increase tobacco treatment use and effectiveness for Veterans in outpatient substance use treatment. The investigators hypothesize that Co-STOP, relative to standard tobacco treatment, will increase tobacco treatment use and quit attempts. This research will help the VA develop effective strategies to promote smoking treatment use and abstinence in Veterans with substance use disorders who smoke, thereby improving rates of morbidity and mortality in Veterans with substance use disorders.

Start Date01 Apr 2027

Sponsor / Collaborator

VA Office of Research and Development

[+1]

NCT06811038

/ Not yet recruitingPhase 3

Providing Nicotine Replacement Therapy to Enhance the Efficacy of a Smoking Cessation Smartphone App for Hispanic Adults

This phase III trial compares a smartphone application with or without nicotine replacement therapy in improving smoking cessation among Hispanic adults who would like to quit smoking. The iCanQuit smartphone application focuses on skills for managing urges, motivation, and relapse prevention with personalized quit plans. Nicotine replacement therapy works by giving small, steady doses of nicotine to help stop cravings and relieve symptoms that occur when a person is trying to quit smoking without any of the other harmful chemicals found in tobacco products.

Start Date15 Oct 2026

Sponsor / Collaborator

Fred Hutchinson Cancer Center

[+1]

100 Clinical Results associated with Nicotine

100 Translational Medicine associated with Nicotine

100 Patents (Medical) associated with Nicotine

31,818

Literatures (Medical) associated with Nicotine

01 Feb 2027·COMPUTATIONAL BIOLOGY AND CHEMISTRY

Integrative network toxicology and virtual knockout analysis suggest TSNA-associated molecular features in large cell neuroendocrine carcinoma

Article

Author: Yang, Gang ; Yu, Jiahui ; Yin, Liuzhe ; Liu, Zhicheng ; Xiong, Zhe ; Wu, Wei

OBJECTIVE:

Electronic nicotine delivery systems (ENDS) may contain or generate low levels of tobacco-specific nitrosamines (TSNAs), including N-nitrosoanatabine (NAT) and N-nitrosoanabasine (NAB), under certain thermal conditions. Given the uncertain long-term carcinogenic effects of ENDS, this study explored potential molecular associations between TSNA-related exposure signatures and LCNEC using an integrative computational framework.

METHODS:

We integrated network toxicology, clinical transcriptomics (GSE1037), and single-cell RNA sequencing (GSE269942) to identify key targets. Protein-protein interaction (PPI) networks and hub genes were established. Interactions between TSNAs and hub targets were validated using molecular docking and 100-ns molecular dynamics (MD) simulations. Potential network-level perturbation effects were explored via scTenifoldKnk-based virtual knockouts (vKO), diagnostic ROC analysis, and CIBERSORT-based immune infiltration analysis.

RESULTS:

Network analysis identified EGFR, CASP3, CCND1, STAT3, and SRC as central toxicological sensors, with MD simulations suggesting stable predicted interactions with NAT and NAB.The PI3K-Akt pathway emerged as a recurrently enriched pathway linking predicted TSNA targets with LCNEC-associated transcriptomic alterations. Single-cell profiling localized the transcriptomic reprogramming-characterized by IGFBP2 upregulation and EDNRB silencing-specifically to malignant LCNEC clusters. EDNRB (AUC=0.954) and IGFBP2 (AUC=0.855) demonstrated high diagnostic accuracy. vKO simulations suggested that IGFBP2 and EDNRB may be associated with network-level perturbations involving growth-related and immune-related genes.Drug screening anchored this signature to nicotine and prioritized EGFR-related inhibitors and natural compounds as hypothesis-generating candidates for further validation.

CONCLUSION:

This study proposes a hypothesis-generating computational model in which TSNA-associated target networks converge on PI3K-Akt-related signaling and the IGFBP2/EDNRB expression axis in LCNEC.These findings provide exploratory molecular evidence that may inform future experimental studies on TSNA-related lung cancer biology and potential biomarker discovery.

01 Jan 2027·JOURNAL OF NEUROSCIENCE METHODS

Passive nicotine vapor exposure model in mice reveals translationally relevant dose-dependent cotinine levels and withdrawal behaviors

Article

Author: La, Tu ; de Guglielmo, Giordano ; Carrette, Lieselot L G ; George, Olivier ; Ambroggi, Frédéric ; Mosquera, Joseph ; China, Lindsey ; Martinez, Angelica R ; Zahedi, Sélène

BACKGROUND:

Nicotine use disorder and electronic cigarette use remain major public health concerns. While passive vapor exposure systems have been developed in rats, efforts to replicate these approaches in mice have produced inconsistent results, with substantial variability in dosing regimens and limited validation using behavioral and biological markers of nicotine dependence.

NEW METHOD:

We characterized a passive vapor exposure model in C57BL/6 J mice using nicotine dose-response paradigms and spontaneous withdrawal measures. Mice (N = 69) were exposed to 0, 5, 15, or 50 mg/mL nicotine vapor in a 1:1 PG/VG base for 1 h, followed by serum cotinine measurement. A separate cohort (N = 18) received nicotine or vehicle vapor for two weeks, followed by assessment of somatic signs, locomotion, anxiety-like behavior, body temperature, and thermal nociception 24 h post-cessation.

RESULTS:

Serum cotinine increased dose-dependently, with males exhibiting higher levels than females at the highest concentration. Both nicotine groups displayed elevated somatic withdrawal scores driven by paw and body tremors. The 15 mg/mL group additionally showed locomotor sensitization and increased nociceptive thresholds. Core body temperature and anxiety-like behavior in the open field were unaffected across all doses.

COMPARISON WITH EXISTING METHODS:

Our system achieves equivalent or greater cotinine levels within a single 1-hour session across a range of translationally relevant doses, without requiring invasive delivery methods.

CONCLUSIONS:

This model produces biologically relevant nicotine exposure and somatic dependence in mice. Affective and physiological withdrawal components were not detected under these conditions and may require longer exposure durations or alternative assays to fully manifest.

01 Jan 2027·TOXICOLOGY

Toxicity of tobacco products and nicotine on neutrophil host defense: An in vivo and in vitro approach

Article

Author: Gonçalves, Carlos Eduardo ; Yonamine, Mauricio ; Gil, Cristiane Damas ; Farsky, Sandra Helena Poliselli ; Fock, Ricardo Ambrósio ; Sandri, Silvana ; Borges, Pâmela Pacassa ; Scharf, Pablo ; Paranhos, Beatriz Aparecida Passos Bismara ; Makiyama, Edson Naoto

Although heated tobacco products (HTPs) reduce combustion-derived toxicants, increasing evidence indicates that they still induce adverse biological effects whose mechanisms remain poorly understood. We previously showed that HTP exposure impairs, whereas conventional cigarette (CC) exposure exacerbates, neutrophil influx into the inflamed synovium of mice with antigen-induced arthritis (AIA). Here, we investigated the effects of HTP vapor, CC smoke, and vaporized nicotine on neutrophil production and function. Naive and AIA mice and bone marrow (BM)-derived neutrophils were exposed to HTP vapor, CC smoke, or vaporized nicotine. Exposures were carried out in nicotine-equivalent model conditions. In vivo, CC exposure enhanced granulopoiesis, whereas HTP exposure impaired this process, as determined by the numbers of blast cells, immature neutrophils, and mature segmented neutrophils in the BM. In contrast, nicotine exposure increased the numbers of blast cells and band neutrophils and reduced mature circulating neutrophils; nonetheless, it did not alter neutrophil recruitment into the inflamed joint cavity. In BM-derived neutrophils, HTP vapor, CC smoke, and nicotine differentially affected neutrophil function. All exposures increased reactive oxygen species production. CC smoke increased ionomycin-induced extracellular DNA release, whereas both HTP vapor and CC smoke impaired chemotaxis. In contrast, nicotine enhanced neutrophil migratory capacity. STAT3 signaling was modulated following CC smoke and nicotine exposure but not HTP vapor. Together, these in vivo and in vitro findings demonstrate that CC smoke, HTP vapor, and nicotine differentially regulate neutrophil biology. Furthermore, these suggest that other constituents besides nicotine contribute substantially to HTP-induced immunotoxicity, providing mechanistic evidence that these products directly interfere with innate immune responses under inflammatory conditions.

232

News (Medical) associated with Nicotine

08 Oct 2026

·www.sciencedaily.com

Nearly 30,000 people tested quit-smoking methods. One stood out

Nicotine e-cigarettes appear to help more smokers quit than patches, gum, and several other common approaches, according to a major review of 80 clinical trials. Researchers say regulated vaping products are not risk-free, but may be a significantly less harmful alternative for people who would otherwise continue smoking.An updated Cochrane review has found that nicotine e-cigarettes may help more people stop smoking than several commonly used approaches, including nicotine gum, nicotine patches, behavioral support, or trying to quit without assistance. Smoking remains the world's leading cause of preventable disease and death. According to the World Health Organization (WHO), it is responsible for more than seven million deaths each year, including 1.6 million deaths among non-smokers exposed to second-hand smoke. The findings come from a living systematic review, meaning researchers continually update the analysis as new evidence becomes available. The latest version included 80 randomized controlled trials involving 29,861 participants, with nine new trials added in this update. Nicotine Vapes Outperform Patches and Gum The researchers found high-certainty evidence that nicotine e-cigarettes produced higher quit rates than nicotine replacement therapy (NRT), such as patches and gum. For every 100 people, nicotine e-cigarettes resulted in about 4 additional people successfully quitting. Nicotine e-cigarettes also performed better than non-nicotine cigarettes, leading to about 2 additional quitters per 100 people. People given e-cigarettes also had higher quit rates than those who received no support or behavioral support (such as individual counseling and group programs). However, the researchers had less confidence in this comparison because of potential bias in how some of the studies were designed. "We have very strong evidence that regulated nicotine e-cigarettes are substantially less harmful than smoking," says Dr. Jamie Hartmann-Boyce, senior author of the review from the University of Massachusetts Amherst. "Based on the consistency of the findings here, it's clear that they are a proven and viable option for people wishing to quit traditional cigarettes. This update includes 9 new trials and our main conclusions haven't changed." What the Evidence Says About Vaping Risks Researchers found no evidence that using e-cigarettes to quit smoking increased the risk of serious harm, although they emphasize that longer-term research is still needed. The conclusions apply specifically to regulated, nicotine-containing e-cigarettes. Illicit products and e-cigarettes containing other substances, such as THC, may present different risks. "It's worth highlighting that our review looks at regulated e-cigarettes containing nicotine, but many of those available on the market do not meet these standards," says Dr. Hartmann-Boyce. "Unlicensed e-cigarettes are potentially dangerous, with issues including unstable batteries and harmful chemicals. Anyone looking to use e-cigarettes to quit smoking should only purchase devices that have been tested and approved by their country's regulatory body. Lists of regulated devices are available from the FDA in the US and MHRA in the UK." Major health organizations and agencies, including the WHO, continue to warn that e-cigarettes expose users to nicotine and other chemicals that can be harmful. Health officials have also raised concerns that e-cigarette use among children and young people can lead to nicotine addiction and later use of tobacco products. A Step Away From Cigarettes, Not a Risk-Free Endpoint The researchers stress that e-cigarettes may not be the best quitting method for everyone. People who want to stop smoking are encouraged to speak with stop-smoking support services or their clinicians about the most appropriate approach. Vaping still carries health risks. However, the authors say those risks are much smaller than the dangers associated with continuing to smoke cigarettes. Dr. Nicola Lindson, lead author of the review based at the University of Oxford, reflects that: "Quitting smoking is hard, and a lot of people who smoke will have tried many times to quit smoking and been unsuccessful. For that reason, it is important that there are a number of different options available to help somebody quit, which could encourage them to keep trying. Although nicotine vapes are unlikely to be completely risk-free, they are less harmful than smoking, and that is the most important comparison to make for people who are still smoking tobacco." Dr. Hartmann-Boyce views switching to e-cigarettes as a possible stage in the process of moving away from smoking, rather than necessarily the final destination. "For somebody who is already addicted to nicotine through cigarettes, having a safer alternative like an e-cigarette is something worth considering, especially when other quit aids have proven unsuccessful. We are currently working on a review of interventions to help people quit vaping, which could be the next step along for people looking to transition to a lower-harm product before quitting nicotine altogether."

Clinical Result

05 Oct 2026

·www.prnewswire.com

Truth Initiative Names Dr. Vaughan Rees as Chief Research Officer

Harvard public health scientist and addiction research leader will lead scientific agenda spanning tobacco, nicotine and broader addiction challenges WASHINGTON, Oct. 5, 2026 /PRNewswire/ -- Truth Initiative, the nation's largest nonprofit public health organization dedicated to preventing youth and young adult nicotine addiction and empowering quitting for all, today announced that Dr. Vaughan Rees will join the organization as Chief Research Officer on October 27, succeeding Dr. Barbara Schillo. Continue Reading Truth Initiative Rees joins Truth Initiative from the Harvard T.H. Chan School of Public Health, where he has served as Director of the Center for Global Tobacco Control since 2015 and is a Senior Lecturer on Social and Behavioral Sciences. A public health scientist and research leader with more than 25 years of experience, Rees brings deep expertise in addiction and behavioral science, tobacco control and regulatory science, prevention, implementation science and public health policy. At Truth Initiative, he will lead the Schroeder Institute, the organization's research and scientific enterprise. "Vaughan is an exceptional scientist and leader whose breadth of expertise is ideally matched to where Truth Initiative is headed," said Kathy Crosby, CEO and president of Truth Initiative. "We have built an extraordinary foundation in tobacco and nicotine science, and as the addiction landscape evolves, we have an opportunity to apply our science, innovation and behavior change expertise more broadly to the addiction challenges affecting young people today, including those related to nicotine, cannabis, opioids and other emerging risks. Vaughan brings the scientific leadership and perspective to help us build on that foundation, advance proven public health interventions that prevent and address addiction, and ensure rigorous evidence informs public health policy, regulation and solutions that improve lives." As Chief Research Officer, Rees will guide the continued evolution of Truth Initiative's scientific agenda through the Schroeder Institute, advancing a multidisciplinary research portfolio encompassing tobacco and nicotine, addiction science, behavioral health, emerging nicotine products, cannabis, polysubstance use and other evolving public health challenges, particularly among youth and young adults. He will also help expand opportunities for externally funded research and scientific collaboration and strengthen Truth Initiative's ability to translate rigorous science into evidence-based interventions and real-world public health impact. "I am honored to join Truth Initiative, an organization with such a strong record of using science to improve public health," said Rees. "I look forward to working with its talented scientists and leaders to better understand the processes that drive addiction and, importantly, translate what we learn into more effective prevention, treatment and public health policy." Throughout his career, Rees has led interdisciplinary research programs and built national and international collaborations spanning addiction science, tobacco regulatory science and public health. At Harvard, his work has included laboratory-based tobacco research examining tobacco products, consumer behavior and questions relevant to tobacco regulation, giving him deep experience at the intersection of science, product regulation and public health policy . As Principal Investigator, he has directed a multidisciplinary research portfolio supported by more than $12 million in external funding and contributed to collaborative research programs exceeding $50 million. He has advised the U.S. Food and Drug Administration, the World Health Organization Framework Convention on Tobacco Control and the National Academies of Sciences, Engineering, and Medicine. Rees' research reflects the breadth he will bring to Truth Initiative. In addition to extensive work in tobacco and nicotine, his research has examined cannabis and nicotine co-use, cannabis retailer availability and broader drug-attributable harms. Rees also brings a strong commitment to developing the next generation of public health scientists. He has mentored more than 60 master's students, 12 doctoral students, postdoctoral fellows and early-career investigators. Rees succeeds Dr. Barbara Schillo, whose excellent leadership has helped build Truth Initiative's strong scientific foundation and advance its national reputation for rigorous, policy-relevant public health research. "Barbara's contributions to Truth Initiative and to the field have been extraordinary," Crosby said. "Her leadership has strengthened our science, developed exceptional researchers and ensured that evidence remains at the heart of our work. We are deeply grateful for all she has contributed, and Vaughan will build on an incredibly strong foundation as we enter this next chapter." About Truth Initiative Truth Initiative® is a national nonprofit public health organization committed to a future free from lifelong addiction, fostering healthier lives and a more resilient nation. Our mission is to prevent youth and young adult nicotine addiction and empower quitting for all. Through our evidence-based, market-leading cessation intervention, EX® Program, and national public education campaigns, we lead the fight against youth and young adult tobacco use. Learn more at truthinitiative.org. SOURCE Truth Initiative 21% more press release views with Request a Demo

Executive Change

09 Sep 2026

·www.prnewswire.com

Global Action to End Smoking Awards Grant to University of Chicago to Increase Living Kidney Donation Through Smoking Cessation

NEW YORK, Sept. 9, 2026 /PRNewswire/ -- Global Action to End Smoking is pleased to announce an innovative grant to The University of Chicago that aims to increase the number of viable living kidney donors by offering comprehensive smoking cessation support, including tobacco harm reduction, for donors who smoke. Continue Reading The Project Donor team at the Illinois Walk for Kidneys. Image courtesy of Project Donor. According to the U.S. Health Resources and Services Administration, more than 109,000 people are awaiting an organ transplant, and of those roughly 95,000 need a kidney transplant. The need for kidney transplants greatly outweighs the supply: In 2023, the Association of Organ Procurement Organizations found that nearly 4,000 individuals in the U.S. passed away while waiting for a kidney donation. Unlike many other organs, kidney donations can come from living or deceased individuals. Willing individuals may donate a kidney to those in need if they meet certain criteria. For example, donation centers typically require donors to abstain from smoking for a sufficient amount of time, as smoking increases the risk of surgical complications to both the donor and the recipient. With Global Action's grant, The University of Chicago will expand smoking cessation assistance for donors who smoke with the goal of increasing the number of kidney transplants. "By offering resources to adults who smoke, this grant work will potentially extend the lives of two major groups: those who can finally receive a kidney donation, and those who are empowered to successfully quit smoking," said Pamela Parizek, Board Chair of Global Action to End Smoking. Global Action's grant will increase the reach of Project Donor, a pilot program created by The University of Chicago. Previously, Project Donor has supported over 2,000 individuals in making lifestyle modifications, such as smoking cessation, to become a living donor, resulting in 240 successful living donations. "We are excited to work with Global Action to support more prospective living donors on their path to stop smoking," said Josie Maier, the Director of Project Donor. "By quitting smoking, prospective donors can become eligible for organ donation and save the life of someone they care about." With Global Action's support, Project Donor will help more potential donors quit smoking and become eligible to donate. The grant work includes creating donor-specific case management training, providing access to additional counseling, distributing free nicotine replacement therapies or other tobacco harm reduction tools where appropriate, and embedding automated referrals to increase the program's reach. Project Donor also will partner with up to 160 U.S. transplant centers to ensure that any potential donors disqualified for smoking are connected to cessation and harm reduction resources as appropriate. "Collectively, public health has made many strides in ending combustible tobacco use, which remains the leading preventable cause of death," said Parizek. "Our grant work with The University of Chicago and Project Donor demonstrates the creative approach we're taking to assist all adults who smoke to quit." Is smoking still a public health problem? Smoking rates have declined over the last 40 years, but progress has stagnated. Roughly 20% of adults across the globe continue to smoke. In the U.S., the smoking rate remains just under 10%. However, smoking rates are disproportionately high in certain populations, including those who live with mental health conditions, substance use disorders or chronic disease; identify as people of color or indigenous people; live in poverty; and/or are members of the LGBTQIA+ community. Why is smoking so dangerous? Smoking a cigarette burns tobacco, which releases thousands of chemicals into the lungs. Many of these chemicals are known to cause long-term health problems, including cancer, heart disease, reproductive challenges, and more. Nicotine is a highly addictive stimulant found in tobacco. Though it is not as dangerous as many of the other chemicals found in cigarettes, it is what makes smoking extremely difficult to quit. Traditional smoking cessation tools include nicotine replacement therapies like gum, patches, or lozenges. Counseling and medications can also help a person who would like to quit. However, if a person can't or won't quit smoking with these approaches, less harmful products containing nicotine may be appropriate tools to help adults who smoke to quit. What is tobacco harm reduction? Tobacco harm reduction is a specific form of harm reduction applied to people who smoke combustible cigarettes. Harm reduction is a concept in public health that acknowledges that certain activities have high risks, and that there are ways to modify these activities to reduce these risks. It is a term that first became common in public health in the 1980s. Examples of harm reduction include providing clean needles for those who use IV drugs, condoms for those who engage in sexual activity, or seatbelts for those riding in a car. Tobacco harm reduction is the concept that for those adults who cannot or will not quit smoking using traditional cessation tools, switching entirely to reduced-risk nicotine options can lower their long-term health risks and help them live longer, healthier lives. These products include e-cigarettes, nicotine pouches, or heated tobacco products. These products aren't entirely safe, but they don't contain as many of the harmful chemicals found in cigarettes. Many health authorities, including the U.S. Food and Drug Administration and the UK's National Health Service, recognize the potential benefit of these tools for adults who smoke. The U.S. FDA has authorized certain reduced-risk nicotine products as less harmful alternative for adults who smoke and switch completely. The UK's NHS states that e-cigarettes can help people who smoke quit and are significantly less risky than cigarettes. What is Global Action to End Smoking? Global Action to End Smoking is a 501(c)(3) charitable grantmaking organization. Our mission is to end combustible tobacco use, which remains the leading preventable cause of death globally. We are accelerating comprehensive, science-based global efforts to end the smoking epidemic. We support all adults who smoke on their unique journeys to quit—no matter where they live or what identities they carry. We want all adults who smoke to feel respected. We understand each person's quit journey is as unique as they are, and their trust must be earned through empathy. Media Contact: Katherine Ellen Foley, Senior Director, Communications 202-215-9971 [email protected] SOURCE Global Action to End Smoking 21% more press release views with Request a Demo

100 Deals associated with Nicotine

External Link

KEGG	Wiki	ATC	Drug Bank
D03365	Nicotine	N07BA01	DB00184

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Smoking Cessation	South Korea	SAEHAN PHARM	28 Aug 2007
Tobacco Use Disorder	Australia	Johnson & Johnson Pacific Pty Ltd.	27 Nov 2001
Nicotine Dependence	United States	Haleon US Capital LLC	13 Jan 1984

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acral Lentiginous Malignant Melanoma	Phase 3	United States	McNeil AB	01 Mar 2011
Dyskinesia, Drug-Induced	Phase 2	United States	Neuraltus Pharmaceuticals, Inc.	01 Oct 2009
Parkinson Disease	Phase 2	United States	Neuraltus Pharmaceuticals, Inc.	01 Oct 2009
Lung Cancer	Phase 1	United States	Pfizer Inc.	16 Jun 2017
disorder of aging	Preclinical	China	The Shenzhen Institutes of Advanced Technology	07 Feb 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05014282 (CTgov)	Not Applicable	Smoking Cessation	512	Counseling+Nicotine patch (Standard Treatment)	ntwhdfxirc = ukuhilberr qydjcnhsjr (laiozgjnmo, hvlilyqpqz - jwcoknibjb) View more	-	25 Sep 2026
				Smartphone-delivered automated treatment+Nicotine patch (Automated Treatment)	ntwhdfxirc = jebzeshpmv qydjcnhsjr (laiozgjnmo, ybrdnyaxdp - huwygcpzax) View more
NCT05430334 (CTgov)	Not Applicable	Nicotine Dependence	142	e-liquid 5 (Placebo - Combination Five - 0μg/s Nicotine Flux)	sxflghitrd(jerjbsvsmn) = quozwmvzju vslwblotcr (qhkglelbks, bmnygyhyez - tbatlegeqz) View more	-	18 Sep 2026
				e-liquid 1 (Combination One - 15μg/s Protonated Nicotine Flux)	sxflghitrd(jerjbsvsmn) = hlylrknxpm vslwblotcr (qhkglelbks, kdrcdtkoll - vpemveioda) View more
NCT02720445 (MIND, CTgov)	Phase 2	Mild cognitive disorder	348	Nicotine Transdermal Patch (Nicotine Transdermal Patch)	jfrmrfmnkm(smgevgjque) = zdjuepustz wpvwylymge (zexydmnhyf, 0.4969) View more	-	17 Sep 2026
				Placebo Patch (Placebo Patch)	jfrmrfmnkm(smgevgjque) = cbyabedxxx wpvwylymge (zexydmnhyf, 0.5065) View more
NCT05206435 (SHINE, CTgov)	Phase 4	Nicotine Dependence	183	Electronic Cigarette (Electronic Cigarettes)	twkwepfirx(ldgeyoznow) = blcazbvpxs jgmutebwhn (tpquelmgnb, .28) View more	-	20 Aug 2026
				Nicotine Lozenge (Nicotine Lozenges)	twkwepfirx(ldgeyoznow) = bitnoeaydf jgmutebwhn (tpquelmgnb, .24) View more
NCT01622998 (STEP, CTgov)	Phase 4	Smoking Cessation	303	NicoDerm Patch (Standard Transdermal NRT Group (UC))	sxjawivijf = ktqttrpypk brbrpzthjg (kcaedbbdnu, cpontdkrkr - wuptpatdfg) View more	-	14 Aug 2026
				NicoDerm Patch (Titrated Transdermal NRT Group (EXP))	sxjawivijf = msncdadtfb brbrpzthjg (kcaedbbdnu, masvoqwppo - ddbqeaqsps) View more
NCT00962988 (CTgov)	Phase 4	Stroke \| Ischemic Attack, Transient \| Smoking Cessation ... View more	194	Cost-Free Pharmacotherapy Group (Cost-Free Group)	xfgxaiiyjn = xlcmdqorjm fskqvfavoe (rpbauoccth, rhlzgqmrbw - sdsoriezpl) View more	-	10 Aug 2026
				Prescription Only Group (Prescription Only Group)	xfgxaiiyjn = pgyxgfqjbn fskqvfavoe (rpbauoccth, pvqbqmycrr - lbaponfpwf) View more
NCT05004662 (CTgov)	Not Applicable	Smoking Cessation	502	Nicotine Patch+Counseling (Standard Treatment)	ethkdjutbu = mgvfjcccjx kriwltsfip (dduulujrot, uocpybzyly - kkhgixzztu) View more	-	04 Aug 2026
				Nicotine patch+Smartphone-delivered automated treatment (Automated Treatment)	ethkdjutbu = fhsjlhwhgw kriwltsfip (dduulujrot, lqsahhmlbv - aqitrrokyu) View more
NCT05130788 (CTgov)	Not Applicable	Smoking Cessation	150	Nicotine Replacement Therapy (NRT) (Intervention Group A (Aim 2))	xrvpkhusjs = vyvmvfsmts zbbswiaybj (iutxbxuveq, tiwnuydcew - uckpmrttyw) View more	-	31 Jul 2026
				Nicotine Replacement Therapy (NRT) (Control Group (Aim 2))	sscksphxwd = csukiveldr zbuffnhbhl (pqyzenwvzv, uqsuoehgrv - jigeaiwrko) View more
NCT03691350 (CTgov)	Early Phase 1	-	66	Bronchoscopy with Bronchoalveolar Lavage (Group I (Usual Cigarette Brand))	fsmsatjsuw(lzviqwozzt) = cszzhdforn lmqzedkeie (dpkantvlyx, 0.3059) View more	-	23 Apr 2026
				Electronic Cigarette (Group II (SREC With Nicotine))	fsmsatjsuw(lzviqwozzt) = rfkhlagetl lmqzedkeie (dpkantvlyx, 0.2939) View more
NCT06051474 (CTgov)	Phase 4	Smoking Cessation \| Smoking \| Nicotine Dependence	23	Nicotine Replacement Product	omdhzjdnei = ilocmziooq ecgiowcmov (qcbuibrbke, rczghaxmca - xkpsygpjqi) View more	-	16 Apr 2026

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis